(Reuters) - Hikma Pharmaceutical Plc (L:HIK) said it would buy nearly the entire share capital of EIMC United Pharmaceuticals, a drugmaker specialising in oncology products, from a consortium of shareholders to strengthen its position in the Egyptian market.
Hikma, which makes and markets branded and non-branded generic and injectable drugs, did not disclose the value of the deal. Hikma's Egyptian unit has presently a 2 percent market share in that country.